Arangalage Dimitri, Pavon Anna Giulia, Hugelshofer Sarah, Desgraz Benoit, Tzimas Georgios, Delyon Julie, Muller Olivier, Obeid Michel, Ribi Camillo, Michielin Olivier, Özdemir Berna C, Monney Pierre
Service de cardiologie, CHUV, 1011 Lausanne.
Département d'oncologie, CHUV, 1011 Lausanne.
Rev Med Suisse. 2020 Jun 3;16(696):1165-1168.
Immune checkpoint inhibitors (ICI) have revolutionized the field of oncology, by reshaping the prognosis of many cancers and are progressively becoming the standard of care. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), of which cardiovascular irAEs are particularly feared. ICI-induced myocarditis is often a diagnostic challenge because of the vast heterogeneity of clinical presentations, and it is associated with a high mortality rate of around 50%. The present article summarizes the cardiac manifestations, the diagnostic strategy and the therapeutic management of patients with ICI-induced myocarditis used in the treatment of cancer.
免疫检查点抑制剂（ICI）通过重塑多种癌症的预后，彻底改变了肿瘤学领域，并逐渐成为标准治疗方法。这些进展的代价之一是出现了一系列新的免疫相关不良事件（irAE），其中心血管irAE尤其令人担忧。ICI诱发的心肌炎往往是一个诊断难题，因为临床表现差异极大，且其死亡率高达50%左右。本文总结了癌症治疗中ICI诱发心肌炎患者的心脏表现、诊断策略及治疗管理。
